Data may lift Lilly’s fortunes in diabetes market-WEB ONLY
Could Eli Lilly be getting some revenge in the diabetes market? The Indianapolis drugmaker released clinical trial data today showing that its long-acting version of Byetta helped patients reduce their blood sugar and weight better than the long-acting insulin Lantus. Lantus, made by France-based Sanofi-Aventis SA, is a drug that stole significant insulin market share […]